FoxP1 Represses MEF2A in Striated Muscle

Mol Cell Biol. 2024;44(2):57-71. doi: 10.1080/10985549.2024.2323959. Epub 2024 Mar 14.

Abstract

Myocyte enhancer factor 2 (MEF2) proteins are involved in multiple developmental, physiological, and pathological processes in vertebrates. Protein-protein interactions underlie the plethora of biological processes impacted by MEF2A, necessitating a detailed characterization of the MEF2A interactome. A nanobody based affinity-purification/mass spectrometry strategy was employed to achieve this goal. Specifically, the MEF2A protein complexes were captured from myogenic lysates using a GFP-tagged MEF2A protein immobilized with a GBP-nanobody followed by LC-MS/MS proteomic analysis to identify MEF2A interactors. After bioinformatic analysis, we further characterized the interaction of MEF2A with a transcriptional repressor, FOXP1. FOXP1 coprecipitated with MEF2A in proliferating myogenic cells which diminished upon differentiation (myotube formation). Ectopic expression of FOXP1 inhibited MEF2A driven myogenic reporter genes (derived from the creatine kinase muscle and myogenin genes) and delayed induction of endogenous myogenin during differentiation. Conversely, FOXP1 depletion enhanced MEF2A transactivation properties and myogenin expression. The FoxP1:MEF2A interaction is also preserved in cardiomyocytes and FoxP1 depletion enhanced cardiomyocyte hypertrophy. FOXP1 prevented MEF2A phosphorylation and activation by the p38MAPK pathway. Overall, these data implicate FOXP1 in restricting MEF2A function in order to avoid premature differentiation in myogenic progenitors and also to possibly prevent re-activation of embryonic gene expression in cardiomyocyte hypertrophy.

Keywords: FOXP1; MEF2; Myogenesis; cardiomyocyte; differentiation; phosphorylation.

MeSH terms

  • Animals
  • Chromatography, Liquid
  • Hypertrophy
  • MEF2 Transcription Factors / genetics
  • Muscle, Skeletal / physiology
  • Myogenin
  • Proteomics*
  • Tandem Mass Spectrometry*

Substances

  • MEF2 Transcription Factors
  • Myogenin

Grants and funding

This research was funded by a Project Grant (PJT-159644) to JCM from the Canadian Institutes of Health Research (CIHR). JCM is a recipient of the McLaughlin Research Chair in the Faculty of Science, York University.